PubRank

Laurent P Rivory

Author PubWeight™ 21.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 2006 1.64
2 Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006 1.51
3 Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003 1.45
4 Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004 1.36
5 The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005 1.14
6 Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008 1.08
7 Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol 2009 0.98
8 Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004 0.95
9 Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 2003 0.94
10 Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 2005 0.91
11 A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol 2005 0.88
12 The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncol Rep 2003 0.87
13 Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Br J Clin Pharmacol 2006 0.87
14 Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. RNA 2009 0.86
15 Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005 0.85
16 Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505. J Biol Chem 2007 0.83
17 The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J Pharmacol Exp Ther 2002 0.81
18 Interfering ribonucleic acids that suppress expression of multiple unrelated genes. BMC Biotechnol 2009 0.79
19 Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines. Oncol Rep 2004 0.78
20 Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. Br J Clin Pharmacol 2004 0.75
21 Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet 2006 0.75
22 Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. J Pharm Pharmacol 2005 0.75
23 Pemetrexed: single-agent and combination phase I study overview. Semin Oncol 2002 0.75
24 Clinical pharmacology. Med J Aust 2002 0.75